Marker Therapeutics, Inc.
جودة البيانات: 83%
MRKR
Nasdaq
Manufacturing
Chemicals
KWD 1.75
▲
KWD 0.29
(19.86%)
القيمة السوقية: 22.64 M
السعر
KWD 1.75
القيمة السوقية
22.64 M
نطاق اليوم
KWD 1.48 — KWD 1.75
نطاق 52 أسبوعًا
KWD 0.81 — KWD 4.07
حجم التداول
728,642
فتح KWD 1.48
متوسط 50 يوم / 200 يوم
KWD 1.48
18.10% above
متوسط 50 يوم / 200 يوم
KWD 1.32
32.58% above
Quick Summary
النقاط الرئيسية
Negative free cash flow of -12.01 M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-84.24%
أقل من متوسط القطاع (-53.41%)
ROIC-70.52%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio6.50
Interest CoverageN/A
التقييم
PE (TTM)
-1.86
أقل من متوسط القطاع (-1.48)
P/B Ratio1.23
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.9 | -1.5 |
| P/B | 1.2 | 1.6 |
| ROE % | -84.2 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -12.16 M |
| ROE | -84.24% | ROA | -66.65% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -12.01 M |
| ROIC | -70.52% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 6.50 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 18.39 M | Tangible Book Value | 18.39 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.86 | Forward P/E | N/A |
| P/B Ratio | 1.23 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -53.06% | ||
| Market Cap | 22.64 M | Enterprise Value | 5.05 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.79 | Revenue / Share | N/A |
| FCF / Share | -0.93 | OCF / Share | -0.93 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 98.77% |
| SBC-Adj. FCF | -12.49 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 0.0 |
| Net Income | -12.16 M | -10.73 M | -8.24 M | -29.93 M | -41.88 M |
| EPS (Diluted) | -0.79 | -1.19 | -0.94 | -3.58 | -0.55 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -12.89 M | -11.12 M | -14.58 M | -29.95 M | -39.48 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 11.80 M | 13.47 M | 10.42 M | 26.14 M | 27.79 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | 2.79 M | 2.15 M |
| Interest Expense | — | — | — | — | — |
| Income Tax | -15,156.0 | 49,953.0 | 3,675.0 | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 19.07 M | 22.02 M | 17.13 M | 34.42 M | 68.14 M |
| Total Liabilities | 2.27 M | 3.46 M | 3.07 M | 14.82 M | 24.15 M |
| Shareholders' Equity | 16.80 M | 18.56 M | 14.05 M | 19.60 M | 43.99 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 16.07 M | 19.19 M | 15.11 M | 11.78 M | 42.35 M |
| Current Assets | 19.07 M | 22.02 M | 17.13 M | 16.62 M | 45.98 M |
| Current Liabilities | 2.27 M | 3.46 M | 3.07 M | 7.78 M | 12.90 M |
{"event":"ticker_viewed","properties":{"ticker":"MRKR","listing_kind":"stock","pathname":"/stocks/mrkr","exchange":"Nasdaq","country":"US"}}